Business Context and Reporting Period
Company: Bausch Health Companies Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 8, 2025
Event: Completion of a private offering of senior secured notes and entry into a new senior secured credit agreement.
Key Financial Metrics and Capital Structure
Debt Issuance and Facilities
- Senior Secured Notes: $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032.
- Term Loan Facility: $3.0 billion 5.5-year senior secured term loan.
- Revolving Credit Facility: $500 million initial commitment (5-year maturity).
- Total New Financing: Approximately $7.9 billion in aggregate principal/commitments.
Interest Rates and Terms
- Notes Interest: 10.000% fixed, payable semi-annually starting October 15, 2025.
- Term Loan Interest: Floating rate (Alternate Base Rate + 5.25% or Term SOFR + 6.25%).
- Revolving Credit Interest: Floating rate (Alternate Base Rate + 3.25% or Term SOFR + 4.25%), subject to step-downs based on leverage ratios.
- Commitment Fees: 0.50% per annum on the Revolving Credit Facility.
Use of Proceeds
Proceeds from the Notes and Term Loan will be used to:
- Repay and terminate the existing credit agreement.
- Redeem multiple existing debt tranches, including 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 6.125% Senior Secured Notes due 2027, 5.750% Senior Secured Notes due 2027, and 9.000% Senior Secured Notes due 2028.
- Pay related fees, premiums, and expenses.
- Fund general corporate purposes.
Material Changes Versus Prior Period
This filing represents a significant refinancing event. The Company has replaced its existing credit agreement and multiple maturing senior notes with a new capital structure consisting of higher-yield long-term notes (10.000%) and a new senior secured credit facility. The filing does not provide comparative revenue, profit, or cash flow metrics for the current period versus the prior period, as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, Risks, and Covenants
Covenants and Financial Maintenance
- Leverage Ratio: The Credit Agreement requires a Blended First Lien Leverage Ratio not to exceed 4.25:1.00. This threshold steps up to 5.75:1.00 on the "Covenant Step-Up Date" (defined as the last day of the first full fiscal quarter after the loss of meaningful exclusivity protection for Xifaxan).
- Liquidity Requirement: On and after the Covenant Step-Up Date, the Company must maintain minimum Liquidity of $400 million.
- Restrictions: Covenants limit additional indebtedness, dividends, equity repurchases, asset sales, and affiliate transactions.
Redemption and Repurchase Provisions
- Optional Redemption: Notes are redeemable after April 15, 2028. Prior to this date, redemption is permitted at 100% principal plus a "make-whole" premium.
- Mandatory Redemption: Required upon receipt of net cash proceeds from the sale of Bausch + Lomb shares (NumberCo Collateral) or dividends exceeding $50 million.
- Change of Control: Holders may require repurchase at 101% of principal plus accrued interest.
Risks and Contingencies
The filing highlights risks associated with the high cost of capital (10% coupon on notes) and strict leverage covenants tied to the performance and exclusivity status of the Xifaxan product line. The Company's ability to service this debt is contingent on cash flows and the potential monetization of its stake in Bausch + Lomb Corporation.
Investor Verification Checklist
- Verify the exact amount of existing debt redeemed and the net cash impact of the refinancing transaction.
- Confirm the current status of Xifaxan regulatory exclusivity to determine the applicable leverage covenant threshold (4.25:1.00 vs. 5.75:1.00).
- Review the Company's current liquidity position to ensure compliance with the $400 million minimum liquidity requirement post-Covenant Step-Up Date.
- Assess the impact of the 10.000% interest rate on future interest coverage ratios and free cash flow.
- Examine the "NumberCo Collateral" (52.5% equity interest in Bausch + Lomb) for potential mandatory redemption triggers if dividends or share sales occur.